Norditropin Dosage
Generic name: SOMATROPIN 5mg in 1.5mL
Dosage form: injection, solution
Drug class: Growth hormones
Medically reviewed by Drugs.com. Last updated on Feb 28, 2024.
Administration and Use Instructions
- •
- Therapy with NORDITROPIN should be supervised by a physician who is experienced in the diagnosis and management of patients with the conditions for which NORDITROPIN is indicated.
- •
- Fundoscopic examination should be performed routinely before initiating treatment with NORDITROPIN to exclude preexisting papilledema, and periodically thereafter.
- •
- Administer NORDITROPIN by subcutaneous injection to the back of the upper arm, abdomen, buttocks, or thigh with regular rotation of injection sites to avoid lipoatrophy.
- •
- Inspect visually for particulate matter and discoloration. NORDITROPIN should be clear and colorless. If the solution is cloudy or contains particulate matter do not use.
- •
- Instructions for delivering the dosage are provided in the PATIENT INFORMATION and INSTRUCTIONS FOR USE leaflets enclosed with the NORDITROPIN FlexPro prefilled pen.
Pediatric Dosage
- •
- Individualize dosage for each patient based on the growth response.
- •
- Divide the calculated weekly NORDITROPIN dosage into equal doses given either 6, or 7 days per week.
- •
- The recommended weekly dose in milligrams (mg) per kilogram (kg) of body weight for pediatric patients is:
- o
- Pediatric GH Deficiency: 0.17 mg/kg/week to 0.24 mg/kg/week (0.024 to 0.034 mg/kg/day)
- o
- Noonan Syndrome: Up to 0.46 mg/kg/week (up to 0.066 mg/kg/day)
- o
- Turner Syndrome: Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)
- o
- Small for Gestational Age (SGA): Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)
- ▪
- In very short pediatric patients, HSDS less than -3, and older pubertal pediatric patients consider initiating treatment with a larger dose of NORDITROPIN (up to 0.067 mg/kg/day). Consider a gradual reduction in dosage if substantial catch-up growth is observed during the first few years of therapy. In pediatric patients less than 4 years of age with less severe short stature, baseline HSDS values between -2 and -3, consider initiating treatment at 0.033 mg/kg/day and titrate the dose as needed.
- o
- Idiopathic Short Stature: Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)
- o
- Prader-Willi Syndrome: 0.24 mg/kg/week (0.034 mg/kg/day)
- •
- Assess compliance and evaluate other causes of poor growth such as hypothyroidism, under-nutrition, advanced bone age and antibodies to recombinant human growth hormone if patients experience failure to increase height velocity, particularly during the first year of treatment.
- •
- Discontinue NORDITROPIN for stimulation of linear growth once epiphyseal fusion has occurred.
Adult Dosage
- •
- Patients who were treated with somatropin for GH deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin for GH deficient adults.
- •
- Consider using a lower starting dose and smaller dose increment increases for geriatric patients as they may be at increased risk for adverse reactions with NORDITROPIN than younger individuals.
- •
- Estrogen-replete women and patients receiving oral estrogen may require higher doses.
- •
- Administer the prescribed dose daily.
- •
- Either of two NORDITROPIN dosing regimens may be used:
- o
- Non-weight based
- ▪
- Initiate NORDITROPIN with a dose of approximately 0.2 mg/day (range, 0.15 mg/day to 0.3 mg/day) and increase the dose every 1-2 months by increments of approximately 0.1 mg/day to 0.2 mg/day, according to individual patient requirements based on the clinical response and serum insulin-like growth factor 1 (IGF-1) concentrations.
- ▪
- Decrease the dose as necessary on the basis of adverse reactions and/or serum IGF-1 concentrations above the age- and gender-specific normal range.
- ▪
- Maintenance dosages will vary considerably from person to person, and between male and female patients.
- o
- Weight-based
- ▪
- Initiate NORDITROPIN at 0.004 mg/kg daily and increase the dose according to individual patient requirements to a maximum of 0.016 mg/kg daily.
- ▪
- Use the patient’s clinical response, adverse reactions, and determination of age- and gender-adjusted serum IGF-1 concentrations as guidance in dose titration.
- ▪
- Not recommended for obese patients as they are more likely to experience adverse reactions with this regimen
More about Norditropin (somatropin)
- Check interactions
- Compare alternatives
- Reviews (3)
- Side effects
- During pregnancy
- Drug class: growth hormones
- Breastfeeding
Patient resources
Other brands
Genotropin, Omnitrope, Saizen, Humatrope, ... +7 more
Professional resources
Other brands
Genotropin, Omnitrope, Saizen, Humatrope, ... +5 more
Other formulations
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.